IQVIA Holdings/$IQV

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About IQVIA Holdings

Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

Ticker

$IQV

Primary listing

NYSE

Industry

Life Sciences Tools & Services

Employees

89,000

ISIN

US46266C1053

IQVIA Holdings Metrics

BasicAdvanced
$27B
21.12
$7.35
1.29
-

What the Analysts think about IQVIA Holdings

Analyst ratings (Buy, Hold, Sell) for IQVIA Holdings stock.

Bulls say / Bears say

IQVIA's Technology & Analytics Solutions (TAS) segment reported a 9.5% revenue increase in Q4 2024, indicating strong demand for its analytics services. (IQVIA Press Release)
The company achieved a 41% year-over-year growth in free cash flow, reaching $2.11 billion in 2024, enhancing its capacity for strategic investments and shareholder returns. (IQVIA Press Release)
IQVIA's R&D Solutions contracted backlog grew to $31.1 billion as of December 31, 2024, up 5.5% year-over-year at constant currency, suggesting sustained future revenue streams. (IQVIA Press Release)
The Research & Development Solutions (R&DS) segment experienced a 1.3% revenue decline in Q4 2024, indicating potential challenges in this key business area. (IQVIA Press Release)
IQVIA's GAAP Net Income for Q4 2024 declined by 6.8% year-over-year, which may raise concerns about profitability trends. (IQVIA Press Release)
The Contract Sales & Medical Solutions (CSMS) segment saw a 4.8% revenue decrease in Q4 2024, reflecting challenges in this part of the business. (IQVIA Press Release)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.

IQVIA Holdings Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

IQVIA Holdings Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IQV

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs